# Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

> **NCT02047253** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 28 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **DRUG:** Acyclovir

## Key facts

- **NCT ID:** NCT02047253
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2017-06-08
- **Final completion:** 2017-07-14
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2018-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02047253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02047253, "Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02047253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*